Literature DB >> 8933225

Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI.

A Ghezzi1, V Torri, M Zaffaroni.   

Abstract

Our study evaluated the frequency of developing multiple sclerosis (MS) after acute isolated optic neuritis (ON), the possible association with risk factors (gender, age), and the diagnostic and prognosis role of paraclinical tests. We studied 100 ON patients (mean age 28.9 years: SD 8.9): 85 patients were regularly followed up. Sixty-six patients underwent multimodality evoked potential (EP) test, examination and brain MRI within six months of the onset of ON. Over a mean follow-up of 5.2 years, MS occurred in 28/85 cases. The risk of developing MS after four years was 0.35 at life-table analysis, regardless of gender or age at the onset of ON. Visual EPs in unaffected eyes were abnormal in 25.4%, brainstem auditory EPs in 6.5% somatosensory EPs in 8.1%, upper limb motor EPs in 6.8% of the tested patients; intrathecal IgG synthesis was revealed in 51.7% and MRI lesions in 73.8%. Fifty-one of the patients who underwent paraclinical tests were followed up for more than one year, and MS occurred in 13 cases. All of these presented MRI lesions, nine intrathecal IgG synthesis, and two abnormal extraocular EPs. The risk of developing MS after four years was 0.33 in patients with MRI lesions; the simultaneous presence of intrathecal IgG synthesis increased the risk to 0.46.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8933225     DOI: 10.1007/bf01999894

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  64 in total

1.  Study of central and peripheral motor conduction in normal subjects.

Authors:  A Ghezzi; L Callea; M Zaffaroni; A Zibetti; R Montanini
Journal:  Acta Neurol Scand       Date:  1991-12       Impact factor: 3.209

2.  Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values.

Authors:  G Tibbling; H Link; S Ohman
Journal:  Scand J Clin Lab Invest       Date:  1977-09       Impact factor: 1.713

3.  Optic neuritis in Orientals and Caucasians.

Authors:  M Alter; J Good; M Okihiro
Journal:  Neurology       Date:  1973-06       Impact factor: 9.910

4.  Acute unilateral retrobulbar neuritis.

Authors:  W J Collis
Journal:  Arch Neurol       Date:  1965-10

5.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

6.  The predictive value of cerebrospinal fluid electrophoresis in 'possible' multiple sclerosis.

Authors:  D Moulin; D W Paty; G C Ebers
Journal:  Brain       Date:  1983-12       Impact factor: 13.501

7.  Optic neuritis and multiple sclerosis.

Authors:  G C Ebers
Journal:  Arch Neurol       Date:  1985-07

8.  Isoelectric focusing of CSF proteins and the future evolution of multiple sclerosis: a clinical follow-up.

Authors:  B Ersmark; A Sidén
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

9.  Progression of optic neuritis to multiple sclerosis: a prospective study in an Italian population.

Authors:  G Mapelli; M Pavoni; P De Palma; R Modestino; V Pavoni
Journal:  Neuroepidemiology       Date:  1991       Impact factor: 3.282

10.  Clinical and magnetic resonance imaging in optic neuritis.

Authors:  L Jacobs; F E Munschauer; S E Kaba
Journal:  Neurology       Date:  1991-01       Impact factor: 9.910

View more
  2 in total

1.  Sudomotor dysfunction in patients with optic neuritis.

Authors:  Anne Saari; Uolevi Tolonen; Eija Pääkkö; Kalervo Suominen; Jukka Jauhiainen; Kyösti A Sotaniemi; Vilho V Myllylä
Journal:  Clin Auton Res       Date:  2010-03-07       Impact factor: 4.435

Review 2.  Depression following a traumatic brain injury: uncovering cytokine dysregulation as a pathogenic mechanism.

Authors:  Colleen N Bodnar; Josh M Morganti; Adam D Bachstetter
Journal:  Neural Regen Res       Date:  2018-10       Impact factor: 5.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.